A Novel LINC00478/LINC01549 Intergenic Region-ALK Fusion Responded Well to Alectinib in a Patient With Lung Adenocarcinoma

被引：3
|
作者：
Peng, Wei [1 ]
Li, Si [2 ]
Li, Lijian [2 ]
Xiao, Mingzhe [2 ]
Zhong, Jincai [1 ,3 ]
机构：
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanning, Peoples R China
[2] Jiangsu Simcere Diagnost Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Nanjing, Peoples R China
[3] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanning 530021, Peoples R China
来源：
JTO CLINICAL AND RESEARCH REPORTS | 2021年 / 2卷 / 01期
关键词：
CRIZOTINIB; KINASE;
D O I：
10.1016/j.jtocrr.2020.100112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 31 条
  • [1] Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report
    Yan, Lingxin
    Zheng, Jiayu
    Pan, Qingyun
    Liang, Yuxian
    Yu, Pengli
    Chen, Quanfang
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient
    Zhai, Xiaoqian
    Wu, Qiang
    Zeng, Zhen
    Suo, Jing
    Lin, Feng
    Zhou, Qinghua
    [J]. LUNG CANCER, 2021, 153 : 171 - 173
  • [3] A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis
    Cheng, Wanwan
    Qian, Chunfa
    Zhang, Haitao
    Meng, Qi
    Yin, Jiani C.
    Fang, Shencun
    [J]. ANTI-CANCER DRUGS, 2022, 33 (10) : 1182 - 1185
  • [4] A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma
    Ting Wang
    Ge Du
    Man Niu
    Rui Liu
    [J]. BMC Pulmonary Medicine, 23
  • [5] A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma
    Wang, Ting
    Du, Ge
    Niu, Man
    Liu, Rui
    [J]. BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [6] A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report
    Chunguang Wang
    Shu Chen
    Qianru He
    Tingting Sun
    Peiran Xu
    [J]. Investigational New Drugs, 2022, 40 : 1350 - 1353
  • [7] Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases
    Liao, Shan
    Sun, Huiying
    Wu, Jianhua
    Lu, Hao
    Fang, Yisheng
    Wang, Yuanyuan
    Liao, Wangjun
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib
    Wang, Yan-li
    Wu, Zhen-zhen
    Zhang, Heng-rui
    Chen, Dong-sheng
    Zhao, Xin
    [J]. LUNG CANCER, 2021, 154 : 216 - 218
  • [9] Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion
    Xinyi Lin
    Xiaojuan Yang
    Yuan Tan
    Qianqian Duan
    Mei He
    [J]. Investigational New Drugs, 2022, 40 : 1160 - 1163
  • [10] DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy
    Zhang, Jiexia
    Huang, Jian
    Li, Qin
    Lin, Huaming
    Luo, Zhiqiang
    Chen, Rongrong
    [J]. LUNG CANCER, 2021, 159 : 171 - 174
1234